orphan drug designation

May 3, 2017May 3, 2017

EMA Grants Orphan Drug Designation for PQR309 Therapeutic In Diffuse Large B-Cell Lymphoma

News

The European Medicines Agency (EMA) has granted Swiss pharmaceutical firm PIQUR Therapeutics orphan drug designation for PQR309 to treat patients with diffuse large B-cell lymphoma (DLBCL). Claudia Pluess, the company’s senior ... Read more

March 14, 2017

FDA Gives Orphan Drug Status to eFT508 for Treating Diffuse Large B-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to eFT508, which treats diffuse large B-cell lymphoma (DLBCL) by inhibiting proteins associated with the disease. The designation is ... Read more

August 23, 2016August 23, 2016

Peripheral T-cell Lymphoma Therapy CD4CAR Granted Orphan Status by FDA

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to iCell Gene Therapeutics‘ Chimeric Antigen Receptor (CAR) engineered T-cells targeting CD4 (CD4CAR) for the treatment of peripheral T-cell lymphoma (PTCL). ... Read more